Patients discontinuing the use of weight-loss drugs such as Wegovy risk regaining their original body weight in about five years, a Novo Nordisk official said on Wednesday.
Novo Nordisk’s Wegovy won U.S. approval in June 2021 with a label that says it can be used for chronic weight management in patients with a body mass index (BMI) of 27 or more who have at least one weight-related ailment, or in any patient with a BMI of 30 or greater.
Drugs that combat obesity could for the first time be included on the World Health Organization's "essential medicines list," used to guide government purchasing decisions in low- and middle-income countries, the U.N. agency told Reuters.